Abstract
Chagas disease is a Neglected Tropical Disease (NTD), and although it is endemic in Latin America, it affects around 6-7 million people worldwide. The treatment of Chagas disease is based on benznidazole and nifurtimox, which are the only available drugs. However, they are not effective during the chronic phase and cause several side effects. Furthermore, BZ promotes cure in 80% of the patients in the acute phase, but the cure rate drops to 20% in adults in the chronic phase of the disease. In this review, we present several studies published in the last six years, which describe the antiparasitic potential of distinct drugs, from the synthesis of new compounds, aiming to target the parasite, as well as the repositioning and the combination of drugs. We highlight several compounds that have shown equivalency or superiority to BZ, which means that they should be further studied, either in vitro or in vivo. Furthermore, we highlight the differences in the effects of BZ on the same strain of T. cruzi, which might be related to methodological differences, such as parasite and cell ratios, host cell type, and the time of adding the drug. In addition, we discussed the wide variety of strains and also the cell types used as host cells, making it difficult to compare the trypanocidal effect of the compounds.
Keywords: Benznidazole, chagas disease, chemotherapy, drug design, synthesis, Trypanosoma cruzi.
Current Pharmaceutical Design
Title:Chagas Disease Chemotherapy: What Do We Know So Far?
Volume: 27 Issue: 38
Author(s): Aline A. Zuma*Wanderley de Souza
Affiliation:
- Laboratorio de Ultraestrutura Celular Hertha Meyer, Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro; Av. Carlos Chagas Filho, 373, Centro de Ciencias da Saude, Cidade Universitaria, Ilha do Fundao, 21491-590, Rio de Janeiro, RJ,Brazil
Keywords: Benznidazole, chagas disease, chemotherapy, drug design, synthesis, Trypanosoma cruzi.
Abstract: Chagas disease is a Neglected Tropical Disease (NTD), and although it is endemic in Latin America, it affects around 6-7 million people worldwide. The treatment of Chagas disease is based on benznidazole and nifurtimox, which are the only available drugs. However, they are not effective during the chronic phase and cause several side effects. Furthermore, BZ promotes cure in 80% of the patients in the acute phase, but the cure rate drops to 20% in adults in the chronic phase of the disease. In this review, we present several studies published in the last six years, which describe the antiparasitic potential of distinct drugs, from the synthesis of new compounds, aiming to target the parasite, as well as the repositioning and the combination of drugs. We highlight several compounds that have shown equivalency or superiority to BZ, which means that they should be further studied, either in vitro or in vivo. Furthermore, we highlight the differences in the effects of BZ on the same strain of T. cruzi, which might be related to methodological differences, such as parasite and cell ratios, host cell type, and the time of adding the drug. In addition, we discussed the wide variety of strains and also the cell types used as host cells, making it difficult to compare the trypanocidal effect of the compounds.
Export Options
About this article
Cite this article as:
Zuma A. Aline*, de Souza Wanderley , Chagas Disease Chemotherapy: What Do We Know So Far?, Current Pharmaceutical Design 2021; 27 (38) . https://dx.doi.org/10.2174/1381612827666210216152654
DOI https://dx.doi.org/10.2174/1381612827666210216152654 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Imaging of Organ Metabolism in Obesity and Diabetes: Treatment Perspectives
Current Pharmaceutical Design S-nitrosation/Denitrosation in Cardiovascular Pathologies: Facts and Concepts for the Rational Design of S-nitrosothiols
Current Pharmaceutical Design Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms
Current Cardiology Reviews Heat Shock Paradox and a New Role of Heat Shock Proteins and their Receptors as Anti-Inflammation Targets
Inflammation & Allergy - Drug Targets (Discontinued) Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Editorial [Hot Topic: Cardiac Cell Therapy: anno 2011 (Executive Guest Editor: Sophie Van Linthout)
Current Pharmaceutical Design Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews Mitochondrial Diseases in Childhood
Current Molecular Medicine Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy The Role of Autophagy in the Gut Pathogens Clearance and Evasion
Current Protein & Peptide Science Crude Venom from Nematocysts of the Jellyfish Pelagia noctiluca as a Tool to Study Cell Physiology
Central Nervous System Agents in Medicinal Chemistry Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry ACE2 and Diabetic Complications
Current Pharmaceutical Design Oxidative Stress and Cardiovascular Aging: Interaction Between NRF-2 and ADMA
Current Cardiology Reviews Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology